Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus CHLOROPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus CHLOROPTIC.
CHLOROMYXIN vs CHLOROPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Chloroptic (chloramphenicol) inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
1 drop (0.5% solution) into the affected eye(s) every 4-6 hours.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function, necessitating frequent dosing (every 4-6 hours) to maintain therapeutic levels.
CHLOROMYXIN is not a recognized drug. No data available.
Primarily renal elimination (70-80% as unchanged drug). Minor biliary/fecal excretion (<10%).
Category C
Category C
Antibiotic
Antibiotic